Stock 002332 ZHEJIANG XIANJU PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Zhejiang Xianju Pharmaceutical Co.,Ltd.

Equities

002332

CNE100000K64

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-07-11 pm EDT 		5-day change 1st Jan Change
11.31 CNY +0.53% Intraday chart for Zhejiang Xianju Pharmaceutical Co.,Ltd. -3.50% -11.43%
May. 30 Zhejiang Xianju Pharmaceutical Co.,Ltd. Announces 2023 Final Profit Distribution on A Shares, Payable on 05 June 2024 CI
May. 22 Zhejiang Xianju Pharmaceutical Co.,Ltd. Approves Cash Dividend for the Year 2023 CI

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • The company returns high margins, thereby supporting business profitability.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Considering the small differences between the analysts' various estimates, the group's business visibility is good.
  • Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last few months, analysts have been revising downwards their earnings forecast.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ZHEJIANG XIANJU PHARMACEUTICAL CO.,LTD. Stock Zhejiang Xianju Pharmaceutical Co.,Ltd.
-11.43% 1.54B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+62.66% 854B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+40.42% 636B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.37% 361B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.16% 324B
B-
ABBVIE INC. Stock AbbVie Inc.
+9.87% 301B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+15.66% 247B
B+
NOVARTIS AG Stock Novartis AG
+17.90% 228B
B-
AMGEN INC. Stock Amgen Inc.
+14.86% 177B
C+
PFIZER, INC. Stock Pfizer, Inc.
+0.45% 164B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
-

Valuation

P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 002332 Stock
  4. Ratings Zhejiang Xianju Pharmaceutical Co.,Ltd.